Is X-linked methyl-CpG binding protein 2 a new target for the treatment of Parkinson's disease.
Lists
Only you see this
Abstract
X-linked methyl-CpG binding protein 2 mutations can induce symptoms similar to those of Parkinson's disease and dopamine metabolism disorders, but the specific role of X-linked methyl-CpG binding protein 2 in the pathogenesis of Parkinson's disease remains unknown. In the present study, we used 6-hydroxydopamine-induced human neuroblastoma cell (SH-SY5Y cells) injury as a cell model of Parkinson's disease. The 6-hydroxydopamine (50 μmol/L) treatment decreased protein levels for both X-linked methyl-CpG binding protein 2 and tyrosine hydroxylase in these cells, and led to cell death. However, overexpression of X-linked methyl-CpG binding protein 2 was able to ameliorate the effects of 6-hydroxydopamine, it reduced 6-hydroxydopamine-induced apoptosis, and increased the levels of tyrosine hydroxylase in SH-SY5Y cells. These findings suggesting that X-linked methyl-CpG binding protein 2 may be a potential therapeutic target for the treatment of Parkinson's disease.
BibTeX
@inproceedings{xie2013is,
author = {Teng Xie and Jie Zhang and Xian-hou Yuan and Jing Yang and Wei Ding and Xin Huang and Yong Hui Wu},
title = {{Is X-linked methyl-CpG binding protein 2 a new target for the treatment of Parkinson's disease.}},
booktitle = {PubMed},
year = {2013},
doi = {10.3969/j.issn.1673-5374.2013.21.003},
}Loading related content...